Pharmacology: Pharmacokinetics — Clinical Reference Document

Pharmacology · Clinical Bases

How it begins

Comprehensive and clinically oriented analysis of LADME processes, fundamental pharmacokinetic parameters, mathematical models of description, special populations and therapeutic applications of drug monitoring.

What it covers

1. Fundamentals of Pharmacokinetics and the LADME Scheme
2. · 1.1 The LADME Scheme: Integrative Conceptual Framework
3. · 1.2 Transmembrane Transport Mechanisms
4. Release and Absorption From the Site of Administration to Systemic Circulation
5. · 2.1 Pharmaceutical Forms and Release
6. · 2.2 Gastrointestinal Absorption Mechanisms
7. · 2.3 Routes of Administration: Pharmacokinetic Characterization
8. · 2.4 Bioavailability (F): Concept, Types and Determinants
9. · 2.5 The First Pass Effect: Hepatic and Intestinal
10. Distribution Volume of Distribution, Protein Binding and Physiological Barriers
11. · 3.1 Apparent Volume of Distribution (Vd)
12. · 3.2 Binding to Plasma Proteins: Albumin, α1-AGP and Lipoproteins
13. · 3.3 The Blood-Brain Barrier (BBB): Structure and Transport
14. · 3.4 Placental Barrier and Breastfeeding: Pharmacological Considerations
15. Metabolism / Biotransformation CYP450 System, Phases I and II, Pharmacogenomics
16. · 4.1 Phase I and Phase II Reactions
17. · 4.2 The CYP450 System: Isoforms, Substrates, Inducers and Inhibitors
18. · 4.3 Pharmacogenetic Polymorphisms of Metabolism
19. · 4.4 Enzyme Inducers and Inhibitors: Mechanisms and Consequences
20. · 4.5 Prodrugs and Active Metabolites: Therapeutic Relevance
21. Excretion Renal, Biliary Elimination and Total Clearance
22. · 5.1 Renal Elimination: The Predominant Mechanism
23. · 5.2 Biliary Excretion and Enterohepatic Circulation
24. · 5.3 Other Excretion Routes
25. · 5.4 Clarification (Cl): Integrative Concept
26. Pharmacokinetic Parameters AUC, Cmax, Tmax, t½, Steady State and Models
27. · 6.1 The Fundamental Parameters of the C-t Curve
28. · 6.2 Steady State (Steady State, Css)
29. · 6.3 Loading Dose and Maintenance Dose
30. · 6.4 Pharmacokinetic Models: Compartments
31. Order 1, Order 0 and Michaelis-Menten Elimination Kinetics: Phenytoin and Ethanol
32. · 7.1 First Order Kinetics (Linear)
33. · 7.2 Zero Order Kinetics (Non-Linear by Saturation)
34. · 7.3 Michaelis-Menten Kinetics: Phenytoin, Ethanol and Non-Linearity
35. Special Populations IR, IH, Pediatrics, Geriatrics, Pregnancy and Obesity
36. · 8.1 Renal Failure (IR): Dose Adjustment
37. · 8.2 Liver Failure (LI): Child-Pugh and MELD
38. · 8.3 Pediatric Pharmacokinetics: From Neonate to Adolescent
39. · 8.4 Geriatrics: The Multiple Pharmacokinetic Changes of Aging
40. · 8.5 Pregnancy and Obesity
41. Comprehensive Clinical Applications TDM, Interactions, Pharmacogenomics and PK/PD
42. · 9.1 Therapeutic Drug Monitoring (TDM)
43. · 9.2 Pharmacokinetic Interactions: Mechanisms and Risk Classification
44. · 9.3 Pharmacogenomics in Clinical Practice: Current Implementation
45. · 9.4 Pharmacokinetics / Pharmacodynamics Integration (PK/PD)